Sandoz launches the 1st version of multiple sclerosis drugs in US
SHARE
, / 1068 0
Sandoz

Sandoz launches the 1st version of multiple sclerosis drugs in US

Novartis International AG/ Sandoz reports US launch of Glatopa(TM), the first generic contender to Copaxone(R) 20mg. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is only in charge of the content of this declaration.

Glatopa is the first FDA-approved, substitutable generic version of Copaxone(R) 20mg - a treatment for relapsing forms of multiple sclerosis.

Sandoz has started shipping to US clients taking after recent FDA approval. Novartis and Sandoz, together are driving access to a full range of differentiated, high-quality MS therapeutic choices, supplemented by a full range of support services.

Holzkirchen, Germany, June 18, 2015 - Sandoz, a Novartis organization, today announced the US launch of Glatopa(TM), the first generic version of TEVA's Copaxone(R) (glatiramer acetate injection) 20 mg/ml one-time-day by day multiple sclerosis treatment.

Peter Goldschmidt, President of Sandoz US said that Sandoz, together with Momenta, is glad to declare the US market launch of a completely substitutable generic version of multiple sclerosis drugs, after taking FDA's approval.

MS is a debilitating disease affecting about a large portion of a million people in the US alone; just 50 per cent of those diagnosed are presently treated.

Glatopa, grew in a joint effort with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including the individuals who have encountered a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

The Sandoz service offering will incorporate financial backers to qualified patients, personalized injection training and 24-hour access to nurses for non-clinical inquiries.

Battling MS, together with different CNS disorders, is integral to the Novartis mission, and Sandoz's Glatopa joins a wide MS portfolio including two approved therapies and one late-arrange development compound.

Copaxone(R) 20mg is TEVA's top seller by far, generating $ 4.1 billion sales in the past four quarters. TEVA is declines by 1 per cent after hours on light volume, where as MNTA is up 3 per cent on increased volume.

Author
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine; she enjoys writing about Unicorns, Silicon Valley, Startups, and Business leaders and innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B. Follow Christy Gren on Twitter, Facebook & Google.

Register today to get full access to:

All articles | Magazine archives | Livestream events | Comments

PASSWORD RESET


Register today to get full access to:

All articles | Magazine archives | Livestream events | Comments

LOGIN